Birchview Capital’s Zenas BioPharma ZBIO Stock Holding History

Birchview Capital’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.37M	Buy	+70,000	New	+$1.57M	0.78%	33
2025 Q4	–	Sell	-16,500	Closed	-$366K	–	80
2025 Q3	$366K	Hold	16,500	–	–	0.28%	55
2025 Q2	$160K	Hold	16,500	–	–	0.16%	62
2025 Q1	$130K	Hold	16,500	–	–	0.11%	61
2024 Q4	$135K	Buy	+16,500	New	+$257K	0.11%	57

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Birchview Capital's ZBIO Position: Q1 2026 in Review

Birchview Capital opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 70,000 shares worth $1.37M. The stake represents 0.78% of the portfolio and ranks #33 among its holdings. This is a return to the name: Birchview Capital previously reported a position in ZBIO as recently as Q3 2025.

Birchview Capital first reported a position in ZBIO in Q4 2024 and has held it in 5 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Birchview Capital held 70,000 shares of Zenas BioPharma worth $1.37M as of Q1 2026.
Zenas BioPharma was a new Birchview Capital position in Q1 2026.
Zenas BioPharma made up 0.78% of Birchview Capital's portfolio in Q1 2026, its #33 holding.
Birchview Capital first reported a position in Zenas BioPharma in Q4 2024 and has held it in 5 quarters since.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.